Biologics

Stem cell-focused oncology company Vor Biopharma made a series of appointments to its leadership team.

The Spine Journal, the official journal of the North American Spine Society, published a DiscGenics study examining preclinical testing for Discogenic Cells, reports OA Online.

Rosalind Franklin University's Chicago Medical School recognized Wayne Olan, MD, as a distinguished alumnus.

Royal Biologics recently launched the Maxx Ultra Cord with clinical applications in spine and neurosurgery.

Drug company Catalent named David Schaffer, PhD, to its biologics advisory board.

Google will no longer allow advertisements for unproven or experimental medical procedures in its search results to prevent clinics from misleading patients, The Verge reports.

Here are four treatments that are in development in the biologics space:

Drugmakers Grünenthal and Mesoblast entered into a partnership to develop a biologics-based treatment for chronic lower back pain.

NervGen Pharma is planning its clinical development strategy for its compound, NVG-291, in spinal cord injury and multiple sclerosis patients.

The U.S. Patent and Trademark Office issued a patent for Lineage Cell Therapeutics' stem cell-derived treatment for spinal cord injury.